Table 2.
Genotypic combinations of the three genotyped variants related with warfarin, in 148 Greek-Cypriot individuals
| Genotypic combinations | No | % | ||
|---|---|---|---|---|
|
VKORC1 -AA |
CYP2C9*2/*2 |
CYP2C9*1/*3 |
0 |
0 |
|
VKORC1 -AA |
CYP2C9*2/*2 |
CYP2C9*1/*1 |
2**** |
1.35 |
|
VKORC1 -AA |
CYP2C9*1/*2 |
CYP2C9*1/*3 |
2**** |
1.35 |
|
VKORC1 -AG |
CYP2C9*1/*2 |
CYP2C9*1/*3 |
2*** |
1.35 |
|
VKORC1 -AG |
CYP2C9*2/*2 |
CYP2C9*1/*1 |
3*** |
2.03 |
|
VKORC1 -AA |
CYP2C9*1/*2 |
CYP2C9*1/*1 |
7*** |
4.73 |
|
VKORC1 -AA |
CYP2C9*1/*1 |
CYP2C9*1/*3 |
10*** |
6.76 |
|
VKORC1 -AG + GG |
CYP2C9*1/*1 |
CYP2C9*1/*3 |
19 |
12.84 |
|
VKORC1 -AA |
CYP2C9*1/*1 |
CYP2C9*1/*1 |
23 |
15.54 |
|
VKORC1 -AG + GG |
CYP2C9*1/*2 + *2/*2 |
CYP2C9*1/*1 |
25 |
16.89 |
|
VKORC1 -AG + GG |
CYP2C9*1/*1 |
CYP2C9*1/*1 |
55 |
37.16 |
| SUM | 148 | 100 | ||
No CYP2C9*3/*3 genotypes were observed.
****Individuals with four risk alleles (2.70%).
***Individuals with three risk alleles (14.87%).